Amit Khot

Summary

Affiliation: Peter MacCallum Cancer Centre
Country: Australia

Publications

  1. ncbi request reprint Romidepsin for peripheral T-cell lymphoma
    Amit Khot
    Peter MacCallum Cancer Centre, Division of Cancer Medicine, Locked Bag 1, A Beckett St, VIC 8006, Australia
    Expert Rev Hematol 6:351-9. 2013
  2. doi request reprint A risk-adapted protocol for delayed administration of filgrastim after high-dose chemotherapy and autologous stem cell transplantation
    Amit Khot
    Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Clin Lymphoma Myeloma Leuk 13:42-7. 2013
  3. doi request reprint Panobinostat in lymphoid and myeloid malignancies
    Amit Khot
    Department of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Expert Opin Investig Drugs 22:1211-23. 2013
  4. ncbi request reprint Romidepsin for cutaneous T-cell lymphoma
    H Miles Prince
    Department of Haematology, Peter MacCallum Cancer Centre, Division Cancer Medicine, St Andrew s Place, East Melbourne, Australia
    Future Oncol 9:1819-27. 2013

Detail Information

Publications4

  1. ncbi request reprint Romidepsin for peripheral T-cell lymphoma
    Amit Khot
    Peter MacCallum Cancer Centre, Division of Cancer Medicine, Locked Bag 1, A Beckett St, VIC 8006, Australia
    Expert Rev Hematol 6:351-9. 2013
    ....
  2. doi request reprint A risk-adapted protocol for delayed administration of filgrastim after high-dose chemotherapy and autologous stem cell transplantation
    Amit Khot
    Department of Haematology, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Clin Lymphoma Myeloma Leuk 13:42-7. 2013
    ..We prospectively explored a strategy that used prophylactic delayed filgrastim only in patients with risk factors...
  3. doi request reprint Panobinostat in lymphoid and myeloid malignancies
    Amit Khot
    Department of Cancer Medicine, Peter MacCallum Cancer Centre, Melbourne, Victoria, Australia
    Expert Opin Investig Drugs 22:1211-23. 2013
    ..Activity has been demonstrated in hematological diseases, such as cutaneous T-cell lymphoma (CTCL), Hodgkin lymphoma (HL), myeloma and myeloid malignancies...
  4. ncbi request reprint Romidepsin for cutaneous T-cell lymphoma
    H Miles Prince
    Department of Haematology, Peter MacCallum Cancer Centre, Division Cancer Medicine, St Andrew s Place, East Melbourne, Australia
    Future Oncol 9:1819-27. 2013
    ..Romidepsin provides a subset of patients with an opportunity for prolonged clinical responses with a tolerable side-effect profile...